In a retrospective analysis of the outcomes of 166 patients treated with CD19-targeting CAR T-cells at the Children’s Hospital of Philadelphia, the CR rate was 93%, and 67 patients experienced disease recurrence, including 39 patients with CD19-negative leukemia. This evidence concerns the gene CD19 and leukemia.